Podcasts about digital diagnostics

Welcome back to The TechLink Health Podcast, where we explore the intersection of health, technology, and innovations that are helping to create the future of healthcare and life sciences! In today's episode we dive into the future of personal health monitoring and connected health with BeamO, the revolutionary compact home health check-up device by Withings, a leader in the health tech space, known for creating connected devices that empower consumers to “make better health part of daily life”. BeamO represents the next step in that journey, with cutting-edge technology designed to give users real-time insights into their health and well-being. The evolution of connected care and the technologies that are paving the way to the future continues to parallel the emerging need for discoverability of devices such as BeamO and the meaningful insights that are creating opportunities for consumers, clinicians, and companies to engage in new ways. In today's episode we dig deeper into these themes and more with Livia Robic, a Biomedical Engineer by training and Product Manager at Withings, as we discuss BeamO in detail, explore its key features, and consider what the future holds for this device in the larger context of connected health. Listen in with us as we dial in on BeamO and it's revolutionary approach as an influencer device in the growing landscape of connected health. BeamO has recently been recognized as one of Time's Best Inventions of 2024: 200 Innovations Changing How We Live and as a CES 2024 award-winner! Other insights range from exploring how connected devices can revolutionize home health while also promoting health equity in medical deserts, to how connected health is increasingly being consumer-driven in a bottoms-up way, leading to demand for health literacy and education, to a growing list of potential risks that will need to be considered as the rate of adoption continues to increase for connected IoHT and IoMT devices. For more details visit TechLink Health on the web or connect with Livia on LinkedIn. This episode was hosted by Dr. Sarah Samaan.

John Bertrand (CEO, Digital Diagnostics) speaks with us about LumineticsCore, an AI diagnostic system that autonomously diagnoses patients for diabetic retinopathy, including macular edema, to detect disease before it leads to blindness. Also, regular contributor Dr. MedLaw discusses the role of private equity in your practice.Enjoy Listening!Let us know what you thought of this week's episode on Twitter: @physicianswkly Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at editorial@physweekly.com! Thanks for listening!

Drs. Braham, Rogu, and Bravo have a fascinating real conversation about Digital Therapeutics. The intersection of digital innovations in pediatric healthcare with a focus on diagnosing and treating autism using AI technology like Canvas DX. It delves into challenges such as scarce specialists, early intervention's significance, regulatory processes, and the evolving role of pediatricians. Additionally, it addresses broader healthcare challenges, including insurance reimbursement complexities, policy considerations, and the pivotal role of collaboration and equity in improving patient outcomes. Dr. Sharief Taraman is the CEO of Cognoa, a leading pediatric behavioral health and data company developing AI-based technologies to enable early and equitable diagnosis and care for children living with developmental and behavioral health conditions.00:00 Welcome and Introduction to Pediatric Innovation Sessions00:33 Introducing Dr. Sharif Taraman: A Journey from Pediatric Neurology to Health Tech Leadership02:28 Exploring the Brain's Complexity and Digital Therapeutics04:21 The Evolution and Impact of Digital Diagnostics and Therapeutics07:05 Navigating the FDA Process and Addressing Pediatric Research Challenges14:01 The Real-World Application of Digital Health Tools in Pediatrics20:51 Addressing the Challenges of Pediatric Healthcare Delivery26:36 The Future of Pediatric Care: Digital Solutions and Systemic Changes32:24 Advocating for Early Prevention and the Role of Primary Care in Pediatric Health40:01 Understanding Care Coordination and the Importance of Early Detection41:13 Exploring the Multifaceted World of Care Coordination43:10 The Impact of Insurance in Care Coordination44:28 Navigating AI and Bias in Healthcare47:48 Innovating Autism Diagnosis with CanvasDX52:19 Challenges and Solutions in Medicaid Coverage01:05:37 The Future of Pediatric Care and Digital HealthSupport the show

The proliferation of emerging technologies within healthcare stands to deliver the promises of increased efficiencies, more accurate diagnostics, and expanded access to care, funneling into an overarching theme of health equity, but the path to the future is still early in the development cycle and there are several challenges as well as opportunities on the horizon.  For one, there's the topics of data integrity and data biases to build sustainable and inclusive models, then there's the need to build out future-of-society models to enhance regulation and moderate the societal transformation process, and at the same time all of this is happening, we will need to rethink the future of work within healthcare and keep an open mind to the possibilities. In this episode, we dig deeper into the latest happenings of AI-Diagnostics and how the technology is shaping the future of health. We'll essentially decode the potential of AI-Diagnostics as told through the story of Digital Diagnostics, a pioneering AI diagnostics company on a mission to transform the accessibility, affordability, equity, and quality of healthcare. This episode's guest is John Bertrand, an experienced business leader at the cross-section of healthcare and technology, and the CEO of Digital Diagnostics.  Through his 15+ years in the healthcare technology industry, John has developed expertise in identifying market opportunities, creating new products, pivoting existing businesses, and building strong teams. Listen in with us as we share a pioneering journey into the emerging realm of AI-driven technologies with a lens into the successes and opportunities that exist to ensure that health outcomes are improved, at scale, in a way that progresses society toward a healthier future for all. Other insights range from the importance of ethics and equity in the building of AI models, to how 5G technologies are helping to improve health outcomes in remote locations, to how gaining industry adoption continues to be one of the biggest hurdles for the jump into the future. Also, what is embedded AI and how can it help to ensure efficiency gains with the technology? For more details visit TechLink Health on the web or connect with John on LinkedIn. This episode was hosted by Dr. Sarah Samaan.

Dr Tom Oakley, founder and chief executive of digital diagnostics specialist Feedback plc, talks Vox through the company's latest results, and how a recent Parliamentary report could prove the catalyst for much-needed investment into the NHS's digital infrastructure. 0:28 Discusses the company's latest results, and why NHS procurement cycles should see an acceleration of business in H2. 1:48 The significance of the All Party Parliamentary group report on Community Diagnostic Centres for Feedback's Bleepa and CareLocker solutions. 5:27 Why the NHS could be at a tipping point for investment into digital solutions to reduce waiting lists and improve patient outcomes. 07:59 Discusses the company's first contract in private healthcare, and how Feedback's “pathway efficiency” are proving of interest to medical insurers. 10:34 The size of the market opportunity in the NHS and beyond. 11:46 Progress on opening up the opportunity in India, including the appointment of a dedicated country managing director and regulatory approval. 14:09 Opportunities in technology licensing.

In this episode of Medsider Radio, we sat down with John Bertrand, the CEO of Digital Diagnostics, a company that is pioneering AI healthcare systems. Its flagship product, LumineticsCore, is an algorithm that autonomously diagnoses patients with diabetic retinopathy. John's career started at Epic Systems, where he rapidly advanced through various roles, focusing on product and business development. His expertise in digital healthcare, honed at Epic, led to his role at 8VC, a Silicon Valley venture capital firm, where he concentrated on artificial intelligence in medical imaging. Eventually joining Digital Diagnostics as CEO, John combined his extensive industry experience with a passion for innovative healthcare technology solutions.In this interview, John shares his insights on aligning products with real-world needs, the importance of stakeholder engagement for adoption and long-term success, and strategies for navigating the extended sales cycles in healthcare technology. Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with John Bertrand.

Affordability, access, and quality are often referred to as the Iron Triangle of healthcare. There are tradeoffs among them and you can improve one or two, but not all three. Seth Rainford (Co-Founder & President, Digital Diagnostics) joins us to discuss how artificial intelligence can break that tradeoff and lead to a new and golden era of medical diagnosis and treatment.ABOUT CARETALK EXECUTIVE FEATURESCaretalk Executive Features is a series where we spotlight innovative companies and leaders working to advance the healthcare field. ABOUT SETH RAINFORDSeth Rainford is the Co-Founder and President at Digital Diagnostics where he focuses on expanding market opportunities and driving operational excellence within the company.Rainford brings more than a decade of executive experience to Digital Diagnostics including the successful management of large-scale P&L's, strong organic & inorganic business development expertise, as well as complex multi-site operations leadership within the healthcare industry.Rainford most recently served as Regional Vice President & General Manager of LabCorp in the Greater Chicago Area, leading a strategic transformation of the Midwest business unit. Previously, he served as Vice President at Northwestern Medicine, where he drove the commercialization and scaling of their outreach diagnostics business.Rainford received his MBA in business administration from Purdue University.ABOUT DIGITAL DIAGNOSTICSDigital Diagnostics Inc. is a pioneering AI diagnostics company on a mission to benefit patients by transforming the accessibility, affordability, equity, and quality of global healthcare through the application of technology in the medical diagnosis and treatment process.Learn more about Digital DiagnosticsGET IN TOUCHBecome a CareTalk sponsorGuest appearance requestsVisit us on the webSubscribe to the CareTalk NewsletterShop official CareTalk merchFOLLOW CARETALKSpotifyApple PodcastsGoogle PodcastsFollow us on LinkedIn#healthcare #medicine #artificialintelligence #healthcareinnovation #healthcaretechnology #healthcarebusiness #healthcareindustry #healthCareTalk: Healthcare. Unfiltered. is produced by Grippi MediaCareTalk: Healthcare. Unfiltered. is produced by Grippi Media

⁠Join our Facebook Crew: https://www.facebook.com/groups/thirdpedalpodcast⁠⁠⁠⁠⁠ In an unplanned side-track, the guys discover an "automotive discussion" section of craigslist, which promptly becomes a new segment for the show called "Digital Diagnostics", where we guess what's going on with terribly described car problems. Then, Zach shares a story about a guy with terrible life decision skills but excellent car taste. Finally, we share some of what we've learned over the years of buying, selling, or trading a car... what works for us, what doesn't, and how to get the best deal! Follow us on social: ⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠TikTok⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠Instagram --- Support this podcast: https://podcasters.spotify.com/pod/show/thirdpedalpodcast/support

Michael D. Abramoff, MD, Ph.D., a visionary retina specialist, computer scientist, and entrepreneur. Dr. Abramoff shares his view of innovation as a series of small steps and how he works to ensure progress at every stage. More about our guest:Michael D. Abramoff, MD, PhD, is a fellowship-trained retina specialist, computer scientist and entrepreneur. He is Founder and Executive Chairman of Digital Diagnostics, the first company ever to receive FDA clearance for an autonomous AI diagnostic system. To transform the quality, accessibility, and affordability of global healthcare through the automation of medical diagnosis and treatment. Dr. Abramoff (gold Fellow ARVO, Fellow IEEE) is the Robert C. Watzke, MD Professor of Ophthalmology and Visual Sciences at the University of Iowa, with a joint appointment in the College of Engineering.Dr. Abramoff is the Founder and Executive Chairman of Digital Diagnostics, the Autonomous AI diagnostics company that was the first in any field of medicine to get FDA clearance for an autonomous AI. In primary care, the AI system can instantaneously diagnose diabetic retinopathy (including macular edema) at the point-of-care. Dr. Abramoff developed an ethical foundation for autonomous AI that was used during the design and validation, and regulatory and payment pathways for autonomous AI. As the author of over 350 peer-reviewed publications in this field, he has been cited over 42,000 times, and is the inventor on 20 issued patents and many patent applications. Dr. Abramoff has mentored dozens of engineering graduate students, ophthalmology residents, and retina fellows. His passion is to use AI to improve the affordability, accessibility and quality of care.Know more about her and their company here: Dr. Michael D. AbramoffDigital DiagnosticsArticle highlight: 1 in 4 People With Diabetes Have This Sight-Threatening Condition, Study Finds------------------------------------------------------------Episode Guide:1:30 - What is Innovation?2:40 - Breaking down the "steps"6:11 - Ensuring progress in every step10:15 - Diabetes Care in the US12:57 - Diabetic Retinopathy14:25 - Benefits of getting more people screened15:57 - Bringing together different domains17:22 - What is a bio-ethicist?20:38 - What isn't innovation?28:59 - What's next for the company?--------------------------OUTLAST Consulting offers professional development and strategic advisory services in the areas of innovation and diversity management.

Juli Goldstein, VP of Government Affairs and Market Access at Digital Diagnostics, an IAMHP Trusted Partner, stops by the podcast to talk about the use of AI to improve access to care and critical eye health outcomes in diabetes patients. 

Dr. Michael Abramoff is a renowned ophthalmologist and medical AI pioneer. In this episode, we explore his groundbreaking work that led to the first FDA-authorized device that does not require a physician, IDx-DR, which detects more than mild diabetic retinopathy from digital images of the eye. Dr. Abramoff also reflects on the challenges of commercialization, AI reimbursement, and the ethical imperatives for AI in health care centered around patient benefit. Dr. Abramoff is the Robert C. Watzke Professor of Ophthalmology and Visual Sciences at the University of Iowa and Founder & Executive Chairman of Digital Diagnostics, an autonomous AI diagnostics company that developed IDx-DR. Transcript

EDX Medical Group PLC CEO Dr Mike Hudson speaks to Proactive about the work the group is doing in digital diagnostics, suggesting that it may appeal to investors looking for a company that is working to "do well and do good." He also explains why he believes the company is in "a unique position in [the] marketplace." #proactiveinvestors #EDX #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

S1E32: On this episode, The Retinator with Michael Abramoff, MD, PhD Founder/Chairman at Digital Diagnostics and host Dr. Nick. Many will have seen the movie series that started with “The Terminator” – almost 40 years old at this point but still poignant in the picture it painted of a world impacted by artificial intelligence that resulted in the mass extinction of human life when the fictional ‘Sky Net' became aware. But is that our future with the rapid advances in machine learning, artificial intelligence, and deep learning? And if so what can we and should we be doing about it. We can have automation that augments our existing resources in healthcare but as Michael points out the benchmark for technology is not to the clinical resources but rather to the clinical outcome. We know our system misses many opportunities for positive intervention, delivering great healthcare but not always equally or uniformly distributed. Your better pill to swallow is to incorporating AI and technology into your organization with transparency and based on ethics. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Welcome to another episode of Entrepreneur Rx, in which John Shufeldt has the privilege of interviewing Dr. Michael Abramoff, Founder and Executive Chairman of Digital Diagnostics, the first AI diagnostics company to receive the FDA authorization for autonomous AI in the nation. Michael reflects on his journey as an MD as well as the applications AI has had in patient outcomes and in research. He also shares how autonomous AI is helping patients get preventative care for diseased that may not have a cure down the road. With 20 patents under his belt, Michael also talks about his process of patenting AI and how groundbreaking that was. Tune in and join this conversation full of advice around.

The question of the day: does 25 people leaving a several 100-person company REALLY count as a “mass exodus”? In this episode, Jess and Matthew find out! Hey – it's the startup world, things explode all the time. Some new deals: Aledade raises $123 million; Tripp raises $11 million; Socially Determined raises $22.7 million; Digital Diagnostics raises $46.3 million.

The question of the day: does 25 people leaving a several 100-person company REALLY count as a “mass exodus”? In this episode, Jess and Matthew find out! Hey – it's the startup world, things explode all the time. Some new deals: Aledade raises $123 million; Tripp raises $11 million; Socially Determined raises $22.7 million; Digital Diagnostics raises $46.3 million.

Techcyte began as an idea to classify white blood cells using computer vision from Dr. Mohamed Salama which was purchased by Ralph Yarro in a technology transfer from the University of Utah in 2013. Since that initial idea, Techcyte has led the cellular digital pathology revolution by combining the knowledge and skills of a lab professional or pathologist with the latest deep learning technologies to provide the healthcare industries with digital diagnostic solutions.Techcyte believes that individual cells hold clues to diagnosing disease. By analyzing cell morphology, phenotypic characteristics can reveal genotype, conditions, and diseases, getting us closer to providing precision medicine. Connect with Ben on Linkedin or follow him on Twitter @ben_cahoon. 

Have you ever had an idea that you just had to make real? No matter what it took… no matter what obstacles were in your way… no matter how many times people told you no… you just couldn't stop until it existed? Well, this is one of those stories. It begins with an idea in 1988 and leads to the first-ever autonomous AI to be approved by the FDA for diagnosis without physician input. Dr. Michael Abramoff, MD, Ph.D. is the Founder and Executive Chairman of Digital Diagnostics, the autonomous AI diagnostics company which was the first in any field of medicine to get FDA authorization for an autonomous AI.  Dr. Abramoff is a neuroscientist, a practicing physician, and holds a Ph.D. in Artificial Intelligence and Machine Learning. In 1988, Michael was working on artificial intelligence during his residency and began to think a computer could diagnose diabetic retinopathy. Given the technology available at the time, this idea may have been a bit of a stretch. Still, Michael set out to prove it could be done. Joining him in this interview is Seth Rainford, the President and COO at Digital Diagnostics.  Seth focuses on expanding market opportunities and driving operational excellence within the company. He brings more than a decade of executive experience to Digital Diagnostics including the successful management of large-scale P&L's, strong organic & inorganic business development expertise, as well as complex multi-site operations leadership within the healthcare industry. In this episode, we talk with Dr. Abramov and Seth about the 30-year journey that led to the founding of Digital Diagnostics, and the first-ever FDA-approved Autonomous AI in healthcare. Plus, we explore the challenges they continue to work through as they commercialize their product to support organizations looking to win in value-based care! Episode Bookmarks: 01:30 Introduction to Dr. Abramoff and Seth Rainford and how the first-ever autonomous AI solution became FDA-approved for diagnosis without physician input 03:30 The scalability of Artificial Intelligence in healthcare and the recent failure of IBM Watson Health 06:00 “We are at an inflection point with AI…specifically with Autonomous AI.” 06:30 The parallel paths between AI and the discovery of DNA and its eventual use in the courtroom. 07:45 Why should we limit diagnosis to human cognition when autonomous AI has been proven to be safe and effective? 08:45 An overview of the history of AI, from advancements in neuroscience and sensory processing, ML, artificial neural networks, to autonomous AI in healthcare. 10:45 Where IBM Watson failed – it started with “glamour AI” (i.e. winning at Jeopardy) instead of trying to solve problems in healthcare 12:00 Most of what we hear about in healthcare is assistive AI -- not autonomous AI. 13:20 There is no need for human oversight in autonomous AI for making FDA-approved diagnoses in healthcare. 15:15 Referencing a recent NEJM Catalyst Op-Ed that criticizes autonomous AI in healthcare 16:30 Lessons learned from the challenges of assistive AI and how the develop of a completely autonomous AI solution started with FDA approval 18:30 “In considering the best ways to improve population health outcomes, we must include autonomous AI.” 19:00 Humans are not necessarily better than AI when it comes to diagnosis of diabetic retinopathy 19:20 Referencing NEJM study using assistive AI diagnosis of breast cancer and how radiologist involvement with AI didn't improve outcomes 22:00 Health inequities with diabetic retinopathy in various minoritized populations 23:00 Recent CMMI focus to advance health equity in value-based care 23:45 “Diabetic Retinopathy is the main cause of blindness and this is disproportionately impacting minorities and rural populations due to lack of access to care.” 25:00 The importance of the diabetic eye exam and how to make testing more accessible through autonomous AI

Our guests are Dr. Garth Bryson Consultant Pathologist and Clinical Director for Laboratory Medicine at the NHS Greater Glasgow and Clyde and Dr. David Harrison, Professor of Pathology from the University of Saint Andrews, and both from ICAIRD - the Industrial Center for Artificial Intelligence Research and Digital Diagnostics a program matching AI solutions and research with health and social care priorities across Scotland. We talk about the long journey of implementing digital pathology in a large health care system, barriers to adoption of digital pathology, the promise of artificial intelligence, the business case for digital pathology – have we finally been able to articulate one? And finally, we discuss our guests' experience so far in creating a digital slide sharing network throughout Scotland.

Meet Michael D. Abramoff, M.D., Ph.D.:Michael D. Abramoff, M.D., Ph.D. is neuroscientist, fellowship-trained retina specialist, and computer engineer. He is the Founder and Executive Chairman at Digital Diagnostics as well as the Robert C. Watzke, M.D., Professor of Ophthalmology and Visual Sciences at the University of Iowa. Previously, he was the Founder, CEO, and Executive Chairman of IDx. Dr. Abramoff received his M.D. from the University of Amsterdam and Ph.D. in Medical Imaging from Utrecht University. Key Insights:Dr. Abramoff's company Digital Diagnostics developed the first FDA approved autonomous AI. Closing the Care Gap. The primary care physicians and endocrinologists most involved in diabetes care lack the expertise to diagnose diabetic retinopathy. Digital Diagnostics' autonomous AI can make that diagnosis in-office, rather than referring the patient out to another specialist. (8:29)Earning Reimbursement. To get buy in from clinicians and the FDA, Digital Diagnostics had to show that their product was safe, effective, and built on diverse data to prevent bias. Additionally, early on they claimed that as creators of the AI, they are liable for its performance. These features eventually led to a CPT code, creating proof of concept and a path for autonomous AI in healthcare. (12:58)Ethics in AI. When hiring engineers and developers, Dr. Abramoff emphasized the importance of ethics. Single characters in their code could make a difference for a patient. Their work at the aggregate needed to represent individual patients and account for their individual experiences. (22:16)This episode is hosted by Suchi Saria, Ph.D. She is a member of the Advisory Council for Day Zero and is the founder and CEO of Bayesian Health. She is also an Associate Professor of computer science, statistics, and health policy, and the Director of the Machine Learning and Healthcare Lab at Johns Hopkins UniversityRelevant Links:Learn more about Digital DiagnosticsLearn more about Dr. AbramoffListen to “Building the First FDA Approved Autonomous AI in Healthcare,” Digital Diagnostics' podcast featuring Dr. Abramoff

Have you ever had an idea that you just had to make real? No matter what it took… no matter what obstacles were in your way… no matter how many times people told you no… you just couldn't stop until it existed? Well, this is one of those stories. It begins with an idea in 1988 and leads to the first-ever autonomous AI to be approved by the FDA for diagnosis without physician input. Dr. Michael Abramoff is a neuroscientist, a practicing physician, and holds a Ph.D. in Artificial Intelligence and Machine Learning. I know… slacker. In 1988, Michael was working on artificial intelligence during his residency and began to think a computer could diagnose diabetic retinopathy. Given the technology available at the time, this idea may have been a bit of a stretch. Still, Michael set out to prove it could be done. On this episode, we talk with Dr. Michael Abramov and Seth Rainford about the 30-year journey that led to the founding of Digital Diagnostics, and the first-ever FDA-approved Autonomous AI in healthcare. Plus, we explore the challenges they continue to work through as they commercialize their product. The journey itself is remarkable and each obstacle and resolution will be relevant to any digital health entrepreneur – especially those in AI and diagnostics. Of our 180 episodes, this is one of my favorite stories so far. It's fascinating, entertaining, and incredibly useful. I hope you benefit from it as much as I did.   Dr. Michael Abramoff, MD, Ph.D. is the Founder and Executive Chairman of Digital Diagnostics Seth Rainford is the President and COO at Digital Diagnostics   For full show notes, links, and resources: https://thehcbiz.com/180-first-fda-approved-autonomous-ai-in-healthcare/

John Bertrand is the CEO of Digital Diagnostics, a pioneering AI diagnostics company on a mission to transform the accessibility, affordability, equity, and quality of healthcare. Bertrand is an experienced business leader at the cross-section of healthcare and technology. Through his 15+ years in the healthcare technology industry, he has developed expertise in identifying market opportunities, creating new products, pivoting existing businesses, and building strong teams. John Bertrand's career began at Epic, a healthcare software company. There Bertrand led cross-functional teams in a variety of product, customer success, and business development roles with a focus on growth. He later served as Executive in Residence at 8VC, a venture capital firm focused on healthcare technology. His time in this space focused on the application of artificial intelligence and computer vision in healthcare.

Seth Rainford is President & COO of Digital Diagnostics, an AI company transforming the accessibility & affordability of healthcare.

Seth Rainford is the President and COO at Digital Diagnostics, a pioneering AI diagnostics company on a mission to transform the accessibility, affordability, equity, and quality of healthcare. At Digital Diagnostics, Rainford focuses on expanding market opportunities and driving operational success within the company. Rainford brings nearly 20 years of executive experience to Digital Diagnostics, including the successful management of large-scale P&L's, strong organic & inorganic business development expertise, as well as complex multi-site operations leadership within the healthcare industry.

Health Logic Interactive Inc (CVE:CHIP.H, OTCMKTS:CHYPF) is developing point-of-care, lab-on-chip, digital diagnostic tools for screening of chronic kidney disease (CKD). Chronic kidney disease, also called chronic kidney failure, describes the gradual loss of kidney function. Unfortunately, this condition is largely undiagnosed. In the early stages of chronic kidney disease, there may be few signs or […]

3Derm is a medical technology company offering a skin imaging system that allows users to take clinical-quality 3D skin images remotely. Dermatologists can use the uploaded images to efficiently monitor high volumes of patients' lesions while reserving in-clinic appointment times for patients whose images indicate a more alarming condition. A week after the interview in August 2020, 3Derm was acquired by autonomous AI platform Digital Diagnostics. 3Derm co-founder and CEO Liz Asai shares how she and her team gained payor buy-in for their product as well as 3Derm's progress on autonomous and assistive AI with a particular focus on inclusivity in diagnosing skin conditions. --- Support this podcast: https://anchor.fm/theia-hc/support

Our guest today is Dr. Michael Abramoff, founder and executive Chairman of Digital Diagnostics  and a professor at the University of Iowa. He describes how Digital Diagnostics won the first FDA's approval for an autonomous medical AI system. He also gives advice on how to deploy medical AI systems and ensure they are useful, reliable and ethically sound.Pranav and Adriel first give an overview of the FDA and IDx-DR, and provide context for the interview, which starts at 12:18. If you like what you hear, let a friend know, subscribe wherever you get your podcasts, and connect with us on Twitter @AIHealthPodcast.

Autism Spectrum Disorder remains a pressing yet elusive spectrum of conditions. In my conversation with Dennis Wall of Stanford University, we discuss the promise of technology- and augmented reality-based systems in both diagnosis and behavioral treatment for affected individuals. He shares the importance of understanding the context in which data is collected, as well as the ability for simple algorithms to yield actionable insights in the clinic. Check out the glossary of terms, definitions, and resources (and get a sneak peak of the future conversations lined up!) here: bit.ly/datapulse-glossary --- Support this podcast: https://anchor.fm/the-data-pulse/support

digital health maven dot edu – episode 6:  January 9, 2019 This episode is the second of a two-part series focusing on an important question: what are some of the ways digital health startups are commercializing their offerings — in other words what are the strategies they are using to make money? The second installment in this series focuses on digital diagnostics. This is an emerging sub-industry populated by innovations that use digital data (especially information captured by mobile and sensors) and technologies that improve our ability to detect and diagnose a range of diseases. The technology backbone for digital diagnostics includes data (biometrics, audio, images), analytics (including machine learning), hardware and software. In this podcast, you'll learn about some standard use cases for digital diagnostics solutions and focus on two common commercialization strategies companies developing these tools are currently pursuing. The digital health maven dot edu podcast is designed to deepen your understanding (and ability to leverage) trends, technologies and innovations that are re-shaping global health. The podcast showcases excerpts from lectures featuring unique digital health market intelligence developed by Fard and other experts related to artificial intelligence, mobile health, voice technologies, Big Data and other fast-moving innovations. Listen to this episode below. About the Host: This podcast is hosted by Fard Johnmar, digital health futurist, researcher, speaker and helper. Learn more about Fard and his work by clicking here. Interested in diving deeper into any of the insights and strategies outlined in the podcast? Get in touch by clicking here. Share This Podcast Additional Digital Health ResourcesWe have published numerous reports, courses, analysis, eBooks and more on the Digital Health Innovation Resources portal. Click here to learn more and register. How to Subscribe to This Podcast The best way to keep up with the Digital Health Maven Podcast is to download our free publication: “The Guide to Embracing Your Inner Digital Health Maven.”  You'll automatically receive updates when new episodes are published.  More importantly, you'll learn about how you can adopt and practice the traits of digital health mavens to ignite your success. And, if you use Google Play, Sticher or iTunes, please review the podcast, as it helps others understand how you're benefiting from the program. –Follow the Podcast on Stitcher –Follow the Podcast via iTunes –Follow the Podcast via Google Play

digital health maven dot edu – episode 4:  November 28, 2018 This episode continues our focus on the emerging world of digital diagnostics. This is a growing sub-sector of technologies that use data, software and devices to (hopefully) improve the detection and diagnosis of cancer, depression, malaria and other conditions. You'll hear about digital diagnostic basics, including its technology backbone. You'll also be provided with a framework — grounded in the patient journey — that will help you understand four critical use cases for digital diagnostics. The digital health maven dot edu podcast is designed to deepen your understanding (and ability to leverage) trends, technologies and innovations that are re-shaping global health. The podcast showcases excerpts from lectures featuring unique digital health market intelligence developed by Fard and other experts related to artificial intelligence, mobile health, voice technologies, Big Data and other fast-moving innovations. Listen to this episode below. About the Host: This podcast is hosted by Fard Johnmar, digital health futurist, researcher, speaker and helper. Learn more about Fard and his work by clicking here. Interested in diving deeper into any of the insights and strategies outlined in the podcast? Get in touch by clicking here. Share This Podcast Additional Digital Health ResourcesWe have published numerous reports, courses, analysis, eBooks and more on the Digital Health Innovation Resources portal. Click here to learn more and register. How to Subscribe to This Podcast The best way to keep up with the Digital Health Maven Podcast is to download our free publication: “The Guide to Embracing Your Inner Digital Health Maven.”  You'll automatically receive updates when new episodes are published.  More importantly, you'll learn about how you can adopt and practice the traits of digital health mavens to ignite your success. And, if you use Google Play, Sticher or iTunes, please review the podcast, as it helps others understand how you're benefiting from the program. –Follow the Podcast on Stitcher –Follow the Podcast via iTunes –Follow the Podcast via Google Play